|Medical Dictionary - Dictionary of Medicine and Human Biology|
1. Deprivation of vitality or of vital properties. 2. In dentistry, the process by which tooth pulp is destroyed; e.g., by chemical means, by infection, or by extirpation.
To deprive of vitality or of vital properties.
Devoid of life; dead.
A continuing process of degeneration or breaking down, in contrast to evolution. SEE ALSO: involution, catabolism. [L. de-volvo, pp. -volutus, to roll down]
Sir James, English chemist, 1842–1923. See D. flask.
Louis H., French physician, 1832–1906. See de Wecker scissors.
A potent synthetic analogue of cortisol, with similar biological action; used as an anti-inflammatory agent and as a test material for adrenal cortical function.
SYN: dextroamphetamine sulfate. d. sodium phosphate the water-soluble ester of d., with the same actions and uses.
dexbrompheniramine maleate (deks′brom-fen-ir′a-men)
The dextrorotatory isomer of brompheniramine; an antihistamine.
dexchlorpheniramine maleate (deks′klor-fen-ir′a-men)
The dextrorotatory isomer of chlorpheniramine; an antihistamine.
Pantothenic acid with –CH2OH replacing the terminal –COOH; a cholinergic agent and a dietary source of pantothenic acid. SYN: panthenol, pantothenyl alcohol.
dexter (D) (deks′ter)
Located on or relating to the right side. [L. fr. dextra, neut. dextrum]
Toward the right side. [L. dexter, right, + ad, to]
Right-handedness; preference for the right hand in performing manual tasks.
1. Any of several water-soluble high molecular weight glucose polymers (average MW 75,000; ranging between 1,000 and 40,000,000) produced by the action of members of the family Lactobacillaceae and certain other microorganisms on sucrose; used in isotonic sodium chloride solution for the treatment of shock, and in distilled water for the relief of the edema of nephrosis; lower molecular weight d. ( e.g., MW 40,000) improves blood flow in areas of stasis by reducing cellular aggregation. 2. Poly(α-1,6-glucose);α-1,6-glucan with branch points (1,2; 1,3; 1,4) and spacing of these characteristic of the species; used as plasma substitutes or expanders. See dextransucrase. d. 110 d. (average MW 110,000) available as 5% solution in water or saline solution; used as a plasma volume expander. d. 40 d. (average MW 40,000) used as a plasma volume expander and blood flow adjuvant. d. 70 d. (average MW 70,000) used as a plasma volume expander. d. 75 d. (average MW 75,000) used as a plasma volume expander. acid d. the product of acid and heat treatment of d.. animal d. SYN: glycogen. blue d. high molecular weight d. containing a blue chlorotriazine dye, Cibacron Blue; used to measure the void volumes in gel filtration columns, as well as checking column packing. d. sulfate the sodium salt of sulfuric acid esters of the polysaccharide d.; it contains not less than 10 units per mg and not less than 14% of sulfate; an anticoagulant.
An enzyme hydrolyzing α-1,6-d-glucosidic linkages in dextran; used in the prevention of caries.
A glucosyltransferase that builds poly(α-1,6-d-glucosyl), i.e., polyglucoses, dextrans, or α-glucans, from sucrose, releasing d-fructose residues.
Nonspecific term for the complex of enzymes that converts dextrose (d-glucose) into lactic acid.
A colloidal solution of ferric hydroxide in complex with partially hydrolyzed dextrin, used in the treatment of iron-deficiency anemia; it is suitable for intravenous administration and contains 20 mg of iron per ml.
A mixture of oligo(α-1,4-d-glucose) molecules formed during the enzymic or acid hydrolysis of starch, amylopectin, or glycogen; on further hydrolysis they are converted into d-glucose. Dextrins are of much lower molecular weight than dextrans, hence are not suitable as plasma expanders; d. (usually white d.) is used in pharmaceutical preparations. SYN: starch gum. acid d. the product of acid and heat treatment of d.. limit d. the polysaccharide fragments remaining at the end (limit) of exhaustive hydrolysis of amylopectin or glycogen by α-1,4-glucan maltohydrolase or β-amylase, which cannot hydrolyze the α-1,6 bonds at branch points; accumulates in individuals with type III glycogen storage disease. SYN: d. limit. Schardinger dextrins cyclic rings of glucose monomer (usually 6 to 8) linked α-1,4; the result of action of Bacillus macerans on starch.
Any of the enzymes catalyzing the hydrolysis of dextrins; e.g., amylo-1,6-glucosidase, dextrin dextranase. limit d. 1. SYN: α-dextrin endo-1,6-α-glucosidase. 2. SYN: oligo-α-1,6-glucosidase.
A glucosyltransferase transferring 1,4-α-d-glucosyl residues, thus catalyzing the synthesis of dextrans (with 1,6 links between monosaccharide units) from dextrins (with 1,4 links) by glucose transfer. SYN: dextrin → dextran transglucosidase, dextrin 6-glucosyltransferase.
dextrin → dextran transglucosidase
SYN: dextrin dextranase.
SYN: dextrin dextranase.
SYN: limit dextrin.
Capable of producing dextrin.
SYN: glycogenosis. debranching deficiency limit d., limit d. SYN: type 3 glycogenosis.
The passage of dextrin in the urine.
1. Prefixes meaning right, toward, or on the right side. 2. Chemical prefixes meaning dextrorotatory. [L. dexter, on the right-hand side]
dextroamphetamine phosphate (deks′tro-am-fet′a-men)
Same actions and uses as dextroamphetamine sulfate. SYN: d-amphetamine phosphate.
Similar in action to racemic amphetamine sulfate, but is more stimulating to the central nervous system; sympathomimetic and appetite depressant. SYN: d-amphetamine sulfate, dexamphetamine.
Displacement of the heart to the right, either as dextroposition, with simple displacement to the right, or as cardiac heterotaxia, with complete transposition of the right and left chambers, resulting in a heart that is the mirror image of a normal heart. SYN: dexiocardia. [dextro- + G. kardia, heart] corrected d. displacement and rotation of the heart into the right side of the chest but without mirror transposition of the cardiac chambers. SYN: dextroversion of the heart, false d., type 3 d.. false d. SYN: corrected d.. isolated d. d. with mirror-image transposition of the cardiac chambers but without displacement of the abdominal viscera. SYN: type 2 d.. mirror image d. perfect right to left congenital reversal of the heart sometimes with other congenital abnormalities, sometimes normal except for position. secondary d. dextroposition of the heart by some disease of the lungs, pleura, or diaphragm. SYN: type 4 d.. type 1 d. SYN: d. with situs inversus. type 2 d. SYN: isolated d.. type 3 d. SYN: corrected d.. type 4 d. SYN: secondary d.. d. with situs inversus displacement of the heart to the right side of the chest with mirror-image transposition of the cardiac chambers together with transposition of the abdominal viscera. SYN: type 1 d..
That part of the electrocardiogram that is derived from the right ventricle.
Having a dominant right cerebral hemisphere.
Rarely used term for indicating right ocular dominance; denoting one who prefers the right eye in monocular work, such as microscopy. SYN: right-eyed. [dextro- + L. oculus, eye]
Rotation of the upper pole of the cornea to the right. See excycloduction. [dextro- + cyclo- + L. duco, pp. ductus, to lead]
Rarely used term for rotation of one eye to the right. [dextro- + L. duco, pp. ductus, to lead]
Condition in which the stomach is displaced to the right; may represent either simple displacement or situs inversus. Usually associated with dextrocardia. [dextro- + G. gaster, stomach]
Electrocardiographic record in an experimental animal representing spread of impulse through the right ventricle alone.
A twisting to the right. [dextro- + L. gyro, pp. -atus, to turn in a circle, fr. gyrus, circle]
SYN: right-handed. [dextro- + L. manus, hand]
dextromethorphan hydrobromide (deks′tro-meth-or′fan hi-dro-bro′mid)
A synthetic morphine derivative used as an antitussive agent. Inferior to codeine but seemingly lacking in dependence production. It has weak central depressant action.
dextromoramide tartrate (deks-tro-mor′a-mid)
A narcotic analgesic related chemically and pharmacologically to methadone.
Denoting one who uses the right leg in preference to the left. SYN: right-footed. [dextro- + L. pes (ped-), foot]
Abnormal right-sided location or origin of a normally left-sided structure, e.g., origin of the aorta from the right ventricle. d. of the heart dextrocardia.
dextropropoxyphene hydrochloride (deks′tro-pro-pok′se-fen)
SYN: propoxyphene hydrochloride.
SYN: propoxyphene napsylate.
A turning or twisting to the right; especially, the clockwise twist given the plane of plane-polarized light by solutions of certain optically active substances. Cf.:levorotation.
Denoting dextrorotation, or certain crystals or solutions capable of such action; as a chemical prefix, usually abbreviated d-. Cf.:levorotatory.
In a direction from right to left. [dextro- + L. sinister, left]
dextrothyroxine sodium (deks-tro-thi-roks′en)
An antihypercholesterolemic agent.
1. A twisting to the right. 2. In ophthalmology, a seldom-used term for a conjugate rotation of the upper pole of both corneas to the right. [dextro- + L. torsio, a twisting]
Turning to the right. [dextro- + G. tropos, a turn]
1. Version toward the right. 2. In ophthalmology, a conjugate rotation of both eyes to the right. [dextro- + L. verto, pp. versus, to turn] d. of the heart SYN: corrected dextrocardia.
Abbreviation for degrees of freedom, under degree.
Abbreviation for decayed and filled teeth. SYN: d. caries index.
Abbreviation for diisopropyl fluorophosphate.
Abbreviation for 2-deoxyglucose.
Abbreviation for deoxyguanylic acid.
Abbreviation for dihydroxyacetone phosphate.
See under antigen.
Abbreviation for dehydro-3-epiandrosterone.
Abbreviation for dehydroepiandrosterone.
Abbreviation for the sulfate salt of dehydroepiandrosterone.
Felix H., Canadian physician and bacteriologist, 1873–1949. See d'Herelle phenomenon, Twort-d'Herelle phenomenon.
Abbreviation for dihydrofolic acid.
Abbreviation for dihydrofolate reductase.
Abbreviation for Doctor of Hygiene.
Abbreviation for dental index.
1. Two, twice. 2. In chemistry, often used in place of bis- when not likely to be confusing; e.g., dichloro- compounds. Cf.:bi-, bis-. [G. dis, two]
Through, throughout, completely. [G. dia, through]
Either d. insipidus or d. mellitus, diseases having in common the symptom polyuria; when used without qualification, refers to d. mellitus. [G. d., a compass, a siphon, d.] adult-onset d. non-insulin-dependent d. mellitus. alimentary d. SYN: alimentary glycosuria. alloxan d. experimental d. mellitus produced in animals by the administration of alloxan, which damages the insulin-producing islet cells of the pancreas. brittle d. d. mellitus in which there are marked fluctuations in blood glucose concentrations that are difficult to control. bronze d. d. mellitus associated with hemochromatosis, with iron deposits in the skin, liver, pancreas, and other viscera, often with severe liver damage and glycosuria. SEE ALSO: hemochromatosis. SYN: bronzed d., bronzed disease. bronzed d. SYN: bronze d.. calcinuric d. SYN: hypercalciuria. chemical d. SYN: latent d.. galactose d. SYN: galactosemia. gestational d. carbohydrate intolerance of variable severity with onset or first recognition during pregnancy.Gestational d. occurs in 3–6% of all pregnancies, and although it typically resolves after delivery, as many as 60% of women with this disorder eventually develop type 2 d.. D. occurring during pregnancy increases the risk of maternal pyelonephritis and of certain congenital anomalies, and is often associated with polyhydramnios and fetal macrosomia, with resultant dystocia. It is recommended that all pregnant women be screened for gestational d. between the 24th and 28th week of pregnancy by determination of the plasma glucose level 1 hour after a 50 g oral glucose load. A level above 140 mg/dL (7.8 mmol/L) is an indication for a 3-hour glucose tolerance test. Gestational d. can usually be managed by diet alone, but insulin is sometimes required. growth-onset d. SYN: insulin-dependent d. mellitus. d. innocens obsolete term for renal glycosuria. d. insipidus chronic excretion of very large amounts of pale urine of low specific gravity, causing dehydration and extreme thirst; ordinarily results from inadequate output of pituitary antidiuretic hormone; the urine abnormalities may be mimicked as a result of excessive fluid intake, as in psychogenic polydipsia. Several types exist: central, neurohypophyseal, and nephrogenic. Autosomal dominant [MIM*125700, *125800, *192340], X-linked [MIM*304800 and *304900], and even autosomal recessive forms [MIM*222000] have been described. SEE ALSO: nephrogenic d. insipidus. insulin-dependent d. mellitus (IDDM) severe d. mellitus, often brittle, usually of abrupt onset during the first two decades of life but can develop at any age; characterized by polydipsia, polyuria, increased appetite, weight loss, low plasma insulin levels, and susceptibility to ketoacidosis; immune-mediated destruction of pancreatic B cells; insulin therapy and dietary regulation are necessary. Term declared obsolete by American D. Association. SYN: growth-onset d., juvenile-onset d., type I d.. insulinopenic d. any form of d. mellitus resulting from inadequate secretion of insulin. d. intermittens d. mellitus in which there are periods of relatively normal carbohydrate metabolism followed by relapses to the previous diabetic state. juvenile d. d. mellitus appearing in a child or adolescent; often fatal before the discovery of insulin, usually of abrupt onset during first or second decades of life; characterized by polyuria, polydipsia, weight loss; usually severe, insulin dependent, and prone to periods of ketoacidosis; can be familial, follow a viral infection such as mumps; thought to be due to virus-induced or immune destruction of pancreatic islets. SYN: type I d. mellitus. juvenile-onset d. SYN: insulin-dependent d. mellitus. ketosis-prone d. type I or juvenile d. mellitus, in which inadequate treatment leads to development of ketoacidosis. ketosis-resistant d. type II or adult onset d. mellitus, in which episodes of ketoacidosis rarely occur. latent d. a mild form of d. mellitus in which the patient displays no overt symptoms, but displays certain abnormal responses to diagnostic procedures, such as an elevated fasting blood glucose concentration or reduced glucose tolerance. Term declared obsolete by American D. Association. SYN: chemical d.. lipoatrophic d. SYN: lipoatrophy. lipogenous d. d. and obesity combined. maturity-onset d. non-insulin-dependent d. mellitus. maturity onset d. of youth a relatively mild, non-insulin requiring form of d. mellitus beginning at a younger age than usual. d. mellitus (DM) a chronic metabolic disorder in which utilization of carbohydrate is impaired and that of lipid and protein enhanced; it is caused by an absolute or relative deficiency of insulin and is characterized, in more severe cases, by chronic hyperglycemia, glycosuria, water and electrolyte loss, ketoacidosis, and coma; long-term complications include neuropathy, retinopathy, nephropathy, generalized degenerative changes in large and small blood vessels, and increased susceptibility to infection. [L. sweetened with honey] D. mellitus affects at least 16 million Americans, ranks seventh as a cause of death in the United States, and costs the national economy over $100 billion yearly. About 95% of persons with DM have type 2, in which the pancreatic beta cells retain some insulin-producing potential, and the rest have type 1, in which exogenous insulin is required for long-term survival. In type 1 DM, which typically causes symptoms before age 25, an autoimmune process is responsible for beta cell destruction. Type 2 DM is characterized by insulin resistance in peripheral tissues as well as a defect in insulin secretion by beta cells. Insulin regulates carbohydrate metabolism by mediating the rapid transport of glucose and amino acids from the circulation into muscle and other tissue cells, by promoting the storage of glucose in liver cells as glycogen, and by inhibiting gluconeogenesis. The normal stimulus for the release of insulin from the pancreas is a rise in the concentration of glucose in circulating blood, which typically occurs within a few minutes after a meal. When such a rise elicits an appropriate insulin response, so that the blood level of glucose falls again as it is taken into cells, glucose tolerance is said to be normal. The central fact in d. mellitus is an impairment of glucose tolerance of such a degree as to threaten or impair health. Revised diagnostic criteria for DM were published by the American D. Association in June 1997. All criteria depend on the glucose concentration of venous plasma. The diagnosis is confirmed when any 2 tests performed on different days yield levels at or above established thresholds: in the fasting state, 126 mg/dL (7.0 mmol/L); 2 hours postprandially (after a 75-g glucose load), or at random, 200 mg/dL (11.1 mmol/L). Long recognized as an independent risk factor for cardiovascular disease, DM is often associated with other risk factors, including disorders of lipid metabolism, obesity, hypertension, and impairment of renal function. Current recommendations for the management of DM emphasize education and individualization of therapy. Controlled studies have shown that rigorous maintenance of plasma glucose levels as near to normal as possible at all times substantially reduces the incidence and severity of long-term complications, particularly microvascular complications (retinopathy, neuropathy, and nephropathy). Such control involves limitation of dietary carbohydrate and saturated fat; monitoring of blood glucose, including self-testing by the patient and periodic determination of glycosylated hemoglobin; and administration of insulin (particularly in type 1 DM), drugs that stimulate endogenous insulin production (in type 2 DM), or both. Some studies suggest that the risk of cardiovascular disease may be increased in some patients by intensive treatment of DM because of elevation of body weight, blood pressure, triglycerides, and total and low-density cholesterol. Pharmaceutical agents developed during the 1990s have improved control of DM by enhancing responsiveness of cells to insulin, counteracting insulin resistance, and reducing postprandial carbohydrate absorption. See Also insulin resistance; alpha-reductase inhibitor. metahypophysial d. 1. d. mellitus caused by large quantities of endogenous or exogenous pituitary growth hormone; 2. term used to designate the irreversible phase of d. mellitus in acromegaly. Mosler d. inosituria with excretion of large quantities of water. nephrogenic d. insipidus [MIM*304800] d. insipidus due to inability of the kidney tubules to respond to antidiuretic hormone; X-linked inheritance, caused by mutation in the vasopressin V2 receptor gene (AVPR2) on Xq. There is also an autosomal dominant form [MIM*125800], caused by mutation in the aquaphorin 2 gene (AQP2) on 12q. SYN: vasopressin-resistant d.. non-insulin-dependent d. mellitus (NIDDM) an often mild form of d. mellitus of gradual onset, usually in obese individuals over age 35; absolute plasma insulin levels are normal to high, but relatively low in relation to plasma glucose levels; ketoacidosis is rare, but hyperosmolar coma can occur; responds well to dietary regulation and/or oral hypoglycemic agents, but diabetic complications and degenerative changes can develop. Term declared obsolete by American D. Association. pancreatic d. 1. d. mellitus demonstrably dependent upon a pancreatic lesion; 2. d. following removal of the pancreas in an animal. phlorizin d. (flo-rid′zin) SYN: phlorizin glycosuria. phosphate d. excessive secretion of phosphate in the urine due to a defect in tubular reabsorption; usually part of a more generalized abnormality, such as Fanconi syndrome. piqûre d. SYN: puncture d.. [Fr.] pregnancy d. subclinical d.. puncture d. experimental d. produced in animals by puncture of the floor of the fourth ventricle of the brain. SYN: piqûre d.. renal d. SYN: renal glycosuria. starvation d. after prolonged fasting, glycosuria following the ingestion of carbohydrate or glucose because of reduced output of insulin and/or reduced rate of glucose metabolism with a reduced ability to form glycogen. steroid d. d. mellitus produced by pharmacological doses of steroid hormones, particularly glucocorticoids or estrogens; characterized by one or more of the typical manifestations of d. mellitus. steroidogenic d. abnormal glucose tolerance, often frank d. mellitus, induced by the metabolic effects of adrenocortical steroid hormones such as cortisone or therapeutic analogues such as prednisone. The effect may be temporary, resolving when the steroid therapy is discontinued, or d. mellitus may persist. subclinical d. a form of d. mellitus that is clinically evident only under certain circumstances, such as pregnancy or extreme stress; persons so afflicted may, in time, manifest more severe forms of the disease. Term declared obsolete by American D. Association. thiazide d. impaired carbohydrate metabolism associated with the use of thiazide diuretic drugs; severe manifestations are seen in persons having d. mellitus, but impairment is mild or absent in nondiabetic individuals. type I d. SYN: insulin-dependent d. mellitus. type II d. non-insulin-dependent d. mellitus. type I d. mellitus SYN: juvenile d.. vasopressin-resistant d. SYN: nephrogenic d. insipidus.
1. Relating to or suffering from diabetes. 2. One who suffers from diabetes.
. . . Feedback